A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

Part of paid clinical trials in Grayslake, Illinois.

Sponsor: AbbVie
Study ID: NCT07071532
Phase: PHASE1
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Bipolar Disorder

Eligibility Criteria

Sex: ALL
Age: 18 Years - 65 Years
Healthy Volunteers: Not accepted

Interventions

ABBV-932 — DRUG
Oral Capsule
Itraconazole — DRUG
Oral Capsule

Study Details

This study will assess the adverse events and how oral ABBV-932 moves through the body when given with oral Itraconazole in adult participants with bipolar disorder.

Key Dates

First listed: Jul 17, 2025
Start date: Aug 21, 2026
Status verified: Aug 2026
Primary completion: Feb 28, 2027
Completion: Feb 28, 2027

Study Design

Enrollment: 20 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Arms

Experimental: ABBV-932 with Itraconazole
Participants will receive ABBV-932 in Period 1 followed by Itraconalzole in combination with ABBV-932 in Period 2.